Spasova S A
Ter Arkh. 2004;76(10):32-6.
To study efficacy and tolerance of pirasidol in elderly patients with somatic diseases and depression.
The study was made in 30 patients over 55 years of age with a mild or moderate depressive episode. The efficacy of a 6 week treatment with pirasidol was assessed by somatic examination, Hamilton depressive scale (17 points), General Clinical Impression Scale, 5-score subjective state scale.
Pirasidol treatment led to a 36% decrease in intake of drugs. The patients took much lower doses of non-narcotic analgetics, nitroglycerine, tranquilizers, enzymatic medicines. The highest efficacy was seen in patients with exacerbation of somatic diseases which reduced faster in addition of pirasidol to somatotropic therapy. Pirasidol is well tolerated, no interaction with other drugs was found.
The antidepressant pirasidol showed efficacy against depression in elderly patients with somatic pathology. It can be recommended as a drug of choice for treatment of depression in elderly patients with somatic diseases.
研究匹拉唑朵对患有躯体疾病和抑郁症的老年患者的疗效及耐受性。
该研究纳入了30例55岁以上患有轻度或中度抑郁发作的患者。通过体格检查、汉密尔顿抑郁量表（17项）、临床总体印象量表、五分主观状态量表评估匹拉唑朵6周治疗的疗效。
匹拉唑朵治疗使药物摄入量减少了36%。患者服用的非麻醉性镇痛药、硝酸甘油、镇静剂、酶类药物剂量大大降低。在躯体疾病加重的患者中疗效最为显著，在生长激素治疗中加用匹拉唑朵后，病情缓解更快。匹拉唑朵耐受性良好，未发现与其他药物有相互作用。
抗抑郁药匹拉唑朵对患有躯体疾病的老年患者的抑郁症有疗效。可推荐作为治疗患有躯体疾病的老年患者抑郁症的首选药物。
